Tuesday, 23 April 2024
Trending

[the_ad_group id="2845"]

Investing

Vivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 million By Investing.com

Pinterest Climbs 2.25% By Investing.com

[the_ad id="21475"]

[ad_1]

In a series of transactions, entities associated with Vivo Capital have sold a significant portion of their holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN), a biopharmaceutical company. The sales, which took place between April 1 and April 3, 2024, amounted to a total of approximately $2.8 million.

The shares were sold at prices ranging from $6.20 to $6.99. The transactions were carried out under a pre-arranged trading plan, which allows insiders to sell shares over a predetermined period of time, providing an affirmative defense against accusations of trading on nonpublic information.

Vivo Opportunity Fund Holdings, L.P., Vivo Capital Fund VIII, L.P., and Vivo Capital Surplus Fund VIII, L.P. were the entities involved in the sales. These entities are associated with Vivo Capital, a healthcare-focused investment firm, and are reported to be ten percent owners of Terns Pharmaceuticals.

The entities sold shares at weighted average prices, with individual transactions occurring at various prices within the given ranges. For instance, on April 1, Vivo Opportunity Fund Holdings, L.P. sold 136,255 shares at an average price of $6.99 per share, while on April 3, they sold 103,870 shares at an average price of $6.20 per share.

These sales are part of a series of planned disposals of Terns Pharmaceuticals stock by Vivo Capital entities, as outlined in their Rule 10b5-1 trading plan established in late 2023. Following these transactions, the entities continue to hold a substantial number of shares in the company, but the exact remaining holdings were not disclosed in the filing.

Investors often monitor insider sales for insights into executives’ and large shareholders’ perspectives on the company’s future performance. However, it is important to note that such sales do not always indicate a lack of confidence in the company and can be motivated by various factors, including diversification of personal investments.

The reporting persons have disclaimed beneficial ownership of the sold securities except to the extent of their pecuniary interest therein. This disclaimer is a routine legal statement that indicates the reporting person does not claim ownership for purposes other than financial gain and is not necessarily an indicator of the reporting person’s view of the company’s prospects.

InvestingPro Insights

Amidst the recent transactions by Vivo Capital entities, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) presents a mixed financial landscape. With a market…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]